PGNYProgyny, Inc.
$27.94+29% 1Y
$27.94
$16.3052 weeks$32.37
The financials
Progyny, Inc. by the numbers
Progyny, Inc. (PGNY) reported revenue of $351M in Q2 2026 (quarter ended Jun 30, 2026), up 5.3% from the same quarter a year earlier. That came with a gross margin of 25% and net income of $28M (8.0% of revenue). For the full year FY2025, revenue was $1.29B (+10% year on year) and net income $59M. Its largest product in Q2 2026 was Fertility Benefit Services at $230M, 66% of the disclosed total, well ahead of Pharmacy Benefit Services at 34%. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $351M | $333M | +5.3% |
| Gross profit | $89M | $79M | +13% |
| Operating income | $40M | $24M | +64% |
| Net income | $28M | $17M | +64% |
| Diluted EPS | $0.34 | $0.19 | +79% |
| Product | Revenue | Share |
|---|---|---|
| Fertility Benefit Services | $230M | 66% |
| Pharmacy Benefit Services | $120M | 34% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $350.5M (+6.7%)
Fertility Benefit Services grew +7.6% year on yearPharmacy Benefit Services +1.2% year on year
Segment Latestquarter on quarteryear on year
- Fertility Benefit Services$230.2M$230.2Mquarter on quarter +9.9%year on year +7.6%+9.9%+7.6%
- Pharmacy Benefit Services$120.3M$120.3Mquarter on quarter +1.0%year on year +1.2%+1.0%+1.2%
On our screens:Cheap stocks by free cash flow yield